{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:27:58Z","timestamp":1775870878807,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.semnephrol.2024.151497","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T21:02:14Z","timestamp":1710363734000},"page":"151497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance"],"prefix":"10.1016","volume":"44","author":[{"given":"Nelson","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Heybeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.semnephrol.2024.151497_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"33","key":"10.1016\/j.semnephrol.2024.151497_bib0002","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0003","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/j.clml.2021.11.002","article-title":"A new reality for multiple myeloma renal failure: US data report on kidney transplant outcomes","volume":"22","author":"Dykes","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151497_bib0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"10.1016\/j.semnephrol.2024.151497_bib0006","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blade","year":"1998","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151497_bib0007","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1038\/bcj.2017.49","article-title":"Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151497_bib0008","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and years of life lost in different age cohorts of patients with multiple myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/j.ajkd.2022.03.010","article-title":"Cancer mortality in people receiving dialysis for kidney failure: an Australian and New Zealand cohort study, 1980-2013","volume":"80","author":"Rosales","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0011","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.ajkd.2022.02.020","article-title":"Cancer risk and mortality in patients with kidney disease: a population-based cohort study","volume":"80","author":"Kitchlu","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1016\/j.semnephrol.2024.151497_bib0012","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0013","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ekir.2020.01.011","article-title":"The role of kidney transplantation in monoclonal Ig deposition disease","volume":"5","author":"Angel-Korman","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151497_bib0016","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.semnephrol.2024.151497_bib0017","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0018","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.canep.2015.08.002","article-title":"Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution","volume":"39","author":"Rios-Tamayo","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0019","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.semnephrol.2024.151497_bib0021","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0022","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151497_bib0023","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-term kidney transplant graft survival-Making progress when most needed","volume":"21","author":"Poggio","year":"2021","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151497_bib0024","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ndt\/11.7.1486","article-title":"Multiple myeloma treatment in dialysis-dependent patients: to transplant or not to transplant?","volume":"11","author":"van Bommel","year":"1996","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000166684","article-title":"Renal transplantation in light-chain multiple myeloma","volume":"3","author":"Walker","year":"1983","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151497_bib0026","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/ndt\/gfac196","article-title":"Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA","volume":"37","author":"Ng","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0027","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ckj\/sfy137","article-title":"Risk of relapse of multiple myeloma following kidney transplantation","volume":"12","author":"Shah","year":"2019","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151497_bib0029","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Schutt","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151497_bib0030","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151497_bib0031","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0032","doi-asserted-by":"crossref","first-page":"e1273","DOI":"10.1097\/TXD.0000000000001273","article-title":"Death with function and graft failure after kidney transplantation: risk factors at baseline suggest new approaches to management","volume":"8","author":"Merzkani","year":"2022","journal-title":"Transplant Direct"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151497_bib0033","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfaa361","article-title":"Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last 2 decades","volume":"37","author":"Chitty","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0034","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ekir.2022.01.003","article-title":"Kidney transplant outcomes of patients with multiple myeloma","volume":"7","author":"Heybeli","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ckj\/sfz128","article-title":"Kidney transplantation for active multiple myeloma or smoldering myeloma: a case\u2013control study","volume":"14","author":"Kormann","year":"2019","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0036","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/bmt.2008.320","article-title":"Acute cellular rejection in a renal allograft immediately following leukocyte engraftment after auto-SCT","volume":"43","author":"Leung","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0037","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma","volume":"69","author":"Lum","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2024.151497_bib0038","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2019-123146","article-title":"Solid organ transplant rejection associated with the use of the immunomodulatory drugs (IMIDs)","volume":"134","author":"Nadeau Nguyen","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0039","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1111\/ajt.15499","article-title":"Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature","volume":"19","author":"Qualls","year":"2019","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0040","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.transproceed.2018.01.014","article-title":"Severe renal allograft rejection resulting from lenalidomide therapy for multiple myeloma: case report","volume":"50","author":"Walavalkar","year":"2018","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0041","doi-asserted-by":"crossref","first-page":"e14541","DOI":"10.1111\/ctr.14541","article-title":"Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: a case series","volume":"36","author":"Dinh","year":"2022","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0042","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0043","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000046254","article-title":"Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature","volume":"21","author":"Short","year":"2001","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0044","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.ajkd.2021.04.015","article-title":"Kidney transplantation in patients with monoclonal gammopathy of renal significance (MGRS)-associated lesions: a case series","volume":"79","author":"Heybeli","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"10.1016\/j.semnephrol.2024.151497_bib0045","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0046","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"issue":"suppl 24","key":"10.1016\/j.semnephrol.2024.151497_bib0047","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1399-0012.2012.01674.x","article-title":"A case of recurrent light chain deposition disease after living-related renal transplantation\u2014detailed process of the recurrence","volume":"26","author":"Horike","year":"2012","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0048","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.ekir.2021.03.002","article-title":"Evidence for transition from light chain deposition disease by immunofluorescence-only to classic light chain deposition disease","volume":"6","author":"Nasr","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"22","key":"10.1016\/j.semnephrol.2024.151497_bib0049","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0051","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1053\/j.ajkd.2021.02.337","article-title":"Kidney transplantation in monoclonal immunoglobulin deposition disease: a report of 6 cases","volume":"78","author":"Molina-Andujar","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151497_bib0052","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/bloodadvances.2020001553","article-title":"Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function","volume":"4","author":"Milani","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0053","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0054","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.kint.2021.02.038","article-title":"Immunofluorescence staining for immunoglobulin heavy chain\/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases","volume":"100","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0056","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.ajkd.2011.05.003","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits recurs or may develop de novo in kidney allografts","volume":"58","author":"Albawardi","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151497_bib0057","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/ckj\/sfv105","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin in renal allografts","volume":"8","author":"Al-Rabadi","year":"2015","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0058","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12882-018-0969-3","article-title":"Clinicopathological analysis of proliferative glomerulonephritis with monoclonal IgG deposits in 5 renal allografts","volume":"19","author":"Wen","year":"2018","journal-title":"BMC Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151497_bib0059","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151497_bib0060","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ekir.2021.05.011","article-title":"Two cases of proliferative glomerulonephritis with monoclonal IgG deposits treated with renin angiotensin inhibition alone with long-term follow-up","volume":"6","author":"Rosenstock","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0061","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0062","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2215\/CJN.05750710","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft","volume":"6","author":"Nasr","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151497_bib0063","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/TP.0000000000002577","article-title":"Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies","volume":"103","author":"Buxeda","year":"2019","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0064","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ckj\/sfx001","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab","volume":"10","author":"Merhi","year":"2017","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0065","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40620-022-01332-x","article-title":"Treatment with bortezomib for recurrent proliferative glomerulonephritis with monoclonal IgG deposits in kidney allograft. Case report and review of the literature","volume":"35","author":"Oki","year":"2022","journal-title":"J Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151497_bib0066","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ekir.2022.07.009","article-title":"Efficacy of immunomodulatory drugs in combination with dexamethasone in proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151497_bib0067","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ekir.2021.05.008","article-title":"Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"6","author":"Almaani","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0068","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1016\/j.semnephrol.2024.151497_bib0069","article-title":"Daratumumab for severe refractory proliferative glomerulonephritis with monoclonal immune deposits (PGNMID) [abstract]","volume":"17","author":"Anand","year":"2017","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151497_bib0070","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2017121319","article-title":"The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases","volume":"29","author":"Sethi","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0071","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0072","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.kint.2018.05.027","article-title":"Conservative treatment for C3 glomerulopathy and monoclonal Ig","volume":"94","author":"Timmermans","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0073","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12882-019-1640-3","article-title":"Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis","volume":"20","author":"Li","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2024.151497_bib0074","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0075","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Fontan","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0076","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151497_bib0077","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/ckj\/sft124","article-title":"Recovery of renal function succeeding stem cell transplant: a case of C3 glomerulonephiritis secondary to monoclonal gammopathy","volume":"6","author":"Andersen","year":"2013","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0078","first-page":"44","article-title":"Treatment of C3 glomerulopathy in adult kidney transplant recipients: a systematic review","volume":"8","author":"Gonzalez Suarez","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0079","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0081","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12882-018-0904-7","article-title":"Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft","volume":"19","author":"Moog","year":"2018","journal-title":"BMC Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0082","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/modpathol.2011.104","article-title":"The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation","volume":"24","author":"Larsen","year":"2011","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151497_bib0083","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.5858\/2007-131-1368-ETPSOI","article-title":"Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy","volume":"131","author":"Kapur","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0084","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.ajkd.2016.04.021","article-title":"Recurrent light chain proximal tubulopathy in a kidney allograft","volume":"68","author":"Angioi","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.kint.2020.07.037","article-title":"Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants","volume":"99","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0086","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/00007890-199612150-00008","article-title":"Renal transplantation in multiple myeloma. Case report and review of the literature","volume":"62","author":"Dagher","year":"1996","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151497_bib0087","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0088","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.it.2017.07.008","article-title":"Mechanisms of mixed chimerism-based transplant tolerance","volume":"38","author":"Zuber","year":"2017","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151497_bib0089","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"issue":"124","key":"10.1016\/j.semnephrol.2024.151497_bib0090","doi-asserted-by":"crossref","first-page":"124ra128","DOI":"10.1126\/scitranslmed.3003509","article-title":"Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation","volume":"4","author":"Leventhal","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0091","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/ajt.13091","article-title":"Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation","volume":"15","author":"Scandling","year":"2015","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151497_bib0092","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/TP.0000000000002669","article-title":"Twenty-year follow-up of histocompatibility leukocyte antigen-matched kidney and bone marrow cotransplantation for multiple myeloma with end-stage renal disease: lessons learned","volume":"103","author":"Spitzer","year":"2019","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0093","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151497_bib0094","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.semnephrol.2024.151497_bib0095","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0096","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.kint.2020.06.036","article-title":"A study from the Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis","volume":"99","author":"Heybeli","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172996","article-title":"Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis","volume":"12","author":"Sidana","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151497_bib0098","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151497_bib0099","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151497_bib0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0101","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0102","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjh.16796","article-title":"Complement as the enabler of carfilzomib-induced thrombotic microangiopathy","volume":"193","author":"Blasco","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12882-020-02226-5","article-title":"Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with eculizumab in multiple myeloma","volume":"22","author":"Rassner","year":"2021","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151497_bib0104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"issue":"20","key":"10.1016\/j.semnephrol.2024.151497_bib0105","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.3390\/jcm11206059","article-title":"Daratumumab interferes with allogeneic crossmatch impacting immunological assessment in solid organ transplantation","volume":"11","author":"Ho","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151497_bib0106","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ajh.26762","article-title":"Risk factors for severe infection and mortality in patients with COVID-19 in patients with multiple myeloma and AL amyloidosis","volume":"98","author":"Ho","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:51:20Z","timestamp":1748357480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929524000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0270929524000147"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151497","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Transplantation in Multiple Myeloma and Monoclonal Gammopathy of Renal Significance","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151497"}}